The surveillance challenge Patients at elevated melanoma risk - those with multiple nevi, personal or family history, or fair skin - require periodic full-body skin examinations. The challenge is detecting new or changing lesions across a patient's entire skin surface from one appointment to the next, relying on clinician memory and patient self-examination. Total body photography (TBP) addresses this by providing a standardized photographic baseline for comparison.
What TBP provides TBP consists of standardized full-body photographs taken at regular intervals, allowing clinicians to compare lesions against the baseline set during subsequent visits. Any new or morphologically changed lesion is flagged for dermoscopy or biopsy. The approach shifts the detection paradigm from static single-timepoint evaluation to dynamic longitudinal monitoring - the same principle that makes it effective.
Systematic review scope This PRISMA-compliant systematic review identified 14 eligible studies encompassing 12,082 participants across TBP surveillance programs worldwide. The review evaluated whether TBP was associated with earlier-stage melanoma detection, examined the number needed to excise (NNE) metric, and assessed study quality across methodological domains.
PRISMA search strategy The review was conducted per PRISMA guidelines, systematically searching major databases for studies reporting melanoma detection outcomes in patients undergoing TBP surveillance. Studies were included if they reported at least one of the following outcomes: melanoma stage at detection, Breslow thickness, proportion of melanoma in situ, or NNE ratio.
Quality assessment domains Study quality was evaluated across five QUADAS-2 methodological domains: patient selection, index test (TBP protocol), reference standard (histopathology), flow and timing, and reporting of applicability concerns. Studies were rated for risk of bias within each domain to contextualize outcome comparisons.
Identified methodological weaknesses The review identified consistent methodological weaknesses across included studies in two domains: flow and timing (whether TBP and comparison imaging were acquired contemporaneously and with consistent protocols) and reference standard (histopathological confirmation not consistently reported for all excised lesions). These weaknesses limit the strength of conclusions that can be drawn.
Breslow thickness findings Across multiple included studies, patients under TBP surveillance showed a trend toward lower Breslow thickness at melanoma diagnosis compared to comparable populations without TBP. Lower Breslow thickness directly correlates with better prognosis and higher 5-year survival rates, making this the most clinically meaningful endpoint in the review.
Higher proportion of melanoma in situ TBP surveillance programs also showed a higher proportion of melanoma in situ (stage 0) among detected cases compared to standard surveillance. In situ melanoma has near-100% cure rates with simple excision, so shifting detection toward this stage represents the ideal outcome of any surveillance program.
Confounding factors Most studies were conducted in specialized melanoma surveillance clinics enrolling high-risk patients, which introduces patient selection bias. Patients who present for TBP surveillance may be more engaged with their skin health, comply with follow-up appointments more reliably, and have higher baseline dermatological awareness than patients in comparison groups without TBP.
What NNE measures The number needed to excise (NNE) is the ratio of benign lesions removed to each melanoma confirmed - a measure of diagnostic precision. A low NNE indicates selective excision with few unnecessary benign biopsies per melanoma diagnosed; a high NNE indicates many false positives requiring biopsy. Lower NNE is preferable because unnecessary excisions carry procedural risk, scarring, cost, and patient anxiety.
NNE range across studies The review found NNE ratios ranging from 3:1 to 14.3:1 across included TBP surveillance programs. This wide range reflects heterogeneity in patient risk profiles, clinical expertise at each center, TBP protocol standardization, and dermoscopy use as an adjunct. Programs with lower NNE ratios achieved more selective biopsy decision-making.
Context of the NNE range The best performing programs at NNE 3:1 represent a high level of diagnostic selectivity - comparable to or better than published NNE benchmarks for dermoscopy-guided surveillance in specialized clinics. The higher NNE programs at 14:1 reflect less selective lesion flagging, similar to general dermatology practice without TBP.
Emerging 3D TBP platforms The review highlights that newer 3D total body photography systems acquire standardized full-body images in a single capture session, solving key limitations of 2D TBP such as inconsistent positioning, missing anatomical sites, and reliance on multiple discrete photographs. Systems like VECTRA and MoleMap use automated image registration to align sequential captures precisely.
AI-powered lesion tracking 3D TBP platforms integrated with AI algorithms can automatically detect and register all visible nevi across the entire body surface, flag newly appeared lesions, and track morphological changes in tracked lesions between visits. This eliminates the clinician's visual memory requirement that limits 2D TBP and enables quantitative change detection.
Clinical impact of AI integration AI-assisted 3D TBP analysis can identify changing lesions invisible to the naked eye across thousands of nevi simultaneously - a task that is cognitively impossible for human observers examining conventional 2D TBP sets. This transforms TBP from a passive reference archive into an active surveillance system with automated change detection.
Randomized controlled trial evidence The included studies were primarily observational, with inherent selection bias. A randomized controlled trial assigning high-risk patients to TBP surveillance versus standard dermoscopy-guided surveillance would definitively establish the additional benefit of TBP and provide the evidence base needed for guideline inclusion and reimbursement decisions.
Protocol standardization The wide NNE variability across studies reflects the absence of standardized TBP acquisition protocols, flagging criteria, and biopsy thresholds. International consensus guidelines defining minimum image quality standards, surveillance intervals, and criteria for lesion flagging would reduce this variability and improve comparability across future studies.
Cost-effectiveness analysis TBP programs require initial photography setup, storage infrastructure, and clinician time for image review. Health economic modeling comparing TBP surveillance against standard dermoscopy follow-up, accounting for the early-detection benefit (reduced stage at diagnosis) against implementation costs, is needed to justify program expansion and insurance coverage.